Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder (SUNRISE 2)

NCT02952820 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT02952820
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02952820 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder (SUNRISE 2)
Lead sponsor
Eisai Inc.
Phase
Phase 3
Overall status
Completed
Start date
November 15, 2016
Completion date
January 8, 2019
Enrollment
971 (actual)
Sites
114

Conditions

As the registry lists them; a condition with its own page is linked.

insomnia disorder